Wednesday, Sep 29, 1999
South San Francisco, Calif. -- September 29, 1999 --Genentech, Inc. (NYSE:DNA) today announced the 1999 Corporate Leadership Award in Science will be conferred on Arthur D. Levinson, Ph.D., chairman and chief executive officer of Genentech by the Irvington Institute for Immunological Research. Levinson and Genentech are being recognized for the company's passion for scientific excellence and its commitment to basic research in the search for new medicines. The Irvington Institute is a non-profit organization committed to funding the studies and training of young immunological investigators of exceptional promise.
"Because of the Institute's mission, we are particularly pleased to be recognized for our dedication to basic, laboratory research," said Levinson. "Genentech is acutely aware that it is only through the dedicated work of the finest scientists that advances are made in the battle against disease."
Current research activities at Genentech that harness the immune system range from an anti-IgE antibody to blunt allergies and asthma to novel treatments for macular degeneration, a sight-robbing disease of the elderly and psoriasis, a chronic skin disorder. Genentech currently markets two monoclonal antibodies for the treatment of metastatic breast cancer and for non-Hodgkin's lymphoma.
Each year, the Irvington Institute selects 12 recipients of three-year grants from up to 120 applicants. The Irvington fellows then continue their research at leading universities and medical centers in the United States, under the direction of senior scientists including Nobel laureates. The intensive effort is directed at launching the fellows post-training careers in both educational institutions and industry.
The Corporate Leadership in Science award will be presented at the Irvington Institute's Annual Awards Dinner at the Pierre Hotel in New York City on Wednesday, September 29. The Institute will also present Max D. Cooper, M.D. of the Howard Hughes Medical Institute at the University of Alabama with the Award for Scientific Leadership in Immunology for his research in hereditary and acquired immune disorders. The Rosenwald Award for Outstanding Philanthropy will be awarded to Mr. and Mrs. Robert Wood Johnson, IV for their support of autoimmune disease research.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the currently marketed biotechnology products stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #